Biogen Idec’s ALS drug Failed Final Clinical Trial

.

Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.

 


Latest News

Sea World Advertisement Says Killer Whales Live as Long in Captivity as in the W
Republican Senator, Ted Cruz to Compete for President’s Post; But Could his Birt
Ruth Porat to be Google’s New CFO
Fresh Competition Force Netflix, Hulu and Amazon to Look for New Technologies an
Cash-strapped Americans turn to Tax Refund Advances
Drone Manufacturers Have an Eye on North Dakota, Testing Ground for Unmanned Air
Tiffany’s Sales Decline due to a Strong Dollar
Bank of New York Mellon will settle Charges of Defrauding Customers for $714
Return Policy for Target’s Owned and Exclusive Brands Extended to One Year
Starbucks “Race Together” Idea Initiated by CEO Gets a Mixed Reaction
Brent Callinicos Uber’s CFO Steps Down to Spend More Time with Family
Even with the Perfect Design, Driverless Cars May Face Rare Circumstances that m